Please login to the form below

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Novartis gained 177Lu-PSMA-617 as part of its $2.1bn acquisition of Endocyte, which had a focus on radiopharmaceutical drugs for cancer, in October 2018. ... At the time, Novartis said radiopharma was a “key growth driver” for its business and that

Latest news

Novartis aims for 10 blockbuster launches by 2020

The year saw it spend $8.7bn on acquiring gene therapy company AveXis and radiotherapy specialists Endocyte for $2.8bn.
Novartis: pipeline will generate 60 filings in three years

Endocyte adding .
Novartis culls pipeline to focus on most transformative science

$8.7bn, and cancer specialist Endocyte for $2.1bn.
Novartis buys cancer specialist Endocyte for $2.1bn

Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver” for its business and that
Merck's vintafolide fails ovarian cancer trial

If vintafolide is dropped, Endocyte will have to refocus its efforts on EC1456, a cancer drug for folate receptor-positive cancers in phase I testing. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

Deal Watch October 2018

Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.
Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

New hires at Bristol-Myers Squibb, Acceleron and FerGene

Prior to Ipsen, he held a number of leadership roles, including executive vice president and president of oncology at Baxalta, and chief commercial officer of Endocyte.
Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly. Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma ... In addition, Endocyte says it has three new drug
Endocyte brings in senior figures from BMS and Amgen

The appointments come at a crucial time for Endocyte as it prepares for the approval and launch of cancer drugs vintafolide (in partnership with Merck &Co) and etarfolatide. ... The two additions follow the hire in July 2012 of Endocyte's first chief

More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Content Editor - Biotechnology: Salary TBC

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...